Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer

We are reporting a case of multifocal reversible leucoencephalopathy syndrome induced by chemotherapy based on Folfox-Bevacizumab regimen. A 44-year-old female, with no history of hypertension, received a chemotherapy based on Folfox-Bevacizumab for her metastatic colon cancer (5 FU: 325 mg/m(2) d1...

Descripción completa

Detalles Bibliográficos
Autores principales: Salmi, Narimane, Elghissassi, Ibrahim, Bellahammou, Khadija, Lakhdissi, Asmaa, Mrabti, Hind, Errihani, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221973/
https://www.ncbi.nlm.nih.gov/pubmed/25400959
http://dx.doi.org/10.1155/2014/391256
_version_ 1782342959814934528
author Salmi, Narimane
Elghissassi, Ibrahim
Bellahammou, Khadija
Lakhdissi, Asmaa
Mrabti, Hind
Errihani, Hassan
author_facet Salmi, Narimane
Elghissassi, Ibrahim
Bellahammou, Khadija
Lakhdissi, Asmaa
Mrabti, Hind
Errihani, Hassan
author_sort Salmi, Narimane
collection PubMed
description We are reporting a case of multifocal reversible leucoencephalopathy syndrome induced by chemotherapy based on Folfox-Bevacizumab regimen. A 44-year-old female, with no history of hypertension, received a chemotherapy based on Folfox-Bevacizumab for her metastatic colon cancer (5 FU: 325 mg/m(2) d1 by intravenous infusion, Oxaliplatin 80 mg/m(2) d1, and Bevacizumab: 7.5 mg/Kg d1). During the fourth cure, she presented delirium, seizures, and visual disturbances. The computed tomography (CT) of the brain showed hypodense lesions of the white matter of frontal, parietal, and occipital lobes, which were bilateral and symmetrical. The clinical table was reversible under symptomatic treatment.
format Online
Article
Text
id pubmed-4221973
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-42219732014-11-16 Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer Salmi, Narimane Elghissassi, Ibrahim Bellahammou, Khadija Lakhdissi, Asmaa Mrabti, Hind Errihani, Hassan Case Rep Oncol Med Case Report We are reporting a case of multifocal reversible leucoencephalopathy syndrome induced by chemotherapy based on Folfox-Bevacizumab regimen. A 44-year-old female, with no history of hypertension, received a chemotherapy based on Folfox-Bevacizumab for her metastatic colon cancer (5 FU: 325 mg/m(2) d1 by intravenous infusion, Oxaliplatin 80 mg/m(2) d1, and Bevacizumab: 7.5 mg/Kg d1). During the fourth cure, she presented delirium, seizures, and visual disturbances. The computed tomography (CT) of the brain showed hypodense lesions of the white matter of frontal, parietal, and occipital lobes, which were bilateral and symmetrical. The clinical table was reversible under symptomatic treatment. Hindawi Publishing Corporation 2014 2014-10-21 /pmc/articles/PMC4221973/ /pubmed/25400959 http://dx.doi.org/10.1155/2014/391256 Text en Copyright © 2014 Narimane Salmi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Salmi, Narimane
Elghissassi, Ibrahim
Bellahammou, Khadija
Lakhdissi, Asmaa
Mrabti, Hind
Errihani, Hassan
Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
title Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
title_full Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
title_fullStr Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
title_full_unstemmed Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
title_short Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
title_sort atypical reversible leucoencephalopathy syndrome after bevacizumab/folfox regimen for metastatic colon cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221973/
https://www.ncbi.nlm.nih.gov/pubmed/25400959
http://dx.doi.org/10.1155/2014/391256
work_keys_str_mv AT salminarimane atypicalreversibleleucoencephalopathysyndromeafterbevacizumabfolfoxregimenformetastaticcoloncancer
AT elghissassiibrahim atypicalreversibleleucoencephalopathysyndromeafterbevacizumabfolfoxregimenformetastaticcoloncancer
AT bellahammoukhadija atypicalreversibleleucoencephalopathysyndromeafterbevacizumabfolfoxregimenformetastaticcoloncancer
AT lakhdissiasmaa atypicalreversibleleucoencephalopathysyndromeafterbevacizumabfolfoxregimenformetastaticcoloncancer
AT mrabtihind atypicalreversibleleucoencephalopathysyndromeafterbevacizumabfolfoxregimenformetastaticcoloncancer
AT errihanihassan atypicalreversibleleucoencephalopathysyndromeafterbevacizumabfolfoxregimenformetastaticcoloncancer

Ejemplares similares